‘A game changer’: TGA approves diabetes drug for CKD

The PBAC has already recommended listing empagliflozin for CKD.
Rachel Fieldhouse
Associate Professor Ralph Audehm
Associate Professor Ralph Audehm.

The TGA has approved empagliflozin to prevent chronic kidney disease progression in adults regardless of diabetes status, in addition to standard care.

Under the expanded indication, doctors can write private scripts for daily empagliflozin 10mg (Jardiance) for patients with stage 2 or 3A chronic kidney disease with a urine albumin to creatinine ratio ≥30mg/g.